About PID

Primary Immunodeficiencies (PIDs) are a diverse group of more than 400 potentially serious, chronic illnesses due to inherited absence or dysregulation of parts of the immune system. Symptoms often appear in childhood, but many can first occur in adult life. PIDs can lead to reduced quality of life and life expectancy due to recurrent, chronic or severe infections, swellings, autoimmune and inflammatory problems and are a significant health burden. 

Individual PIDs are rare, including many with only a few patients identified in the world, whilst the more common PIDs affect between 1 in 10,000 and 1 in 1,000,000 people. However, taken together, the prevalence of PIDs is overall estimated to be 1 in 1,000 people.

There are six main types of PIDs that affect the immune system in different ways:

  • Predominantly antibody deficiencies e.g. common variable immunodeficiency (CVID)
  • Combined immunodeficiencies e.g. severe combined immunodeficiency (SCID)
  • Phagocytic cell deficiencies e.g. chronic granulomatous disease (CGD)
  • Immune dysregulation e.g. autoimmune lymphoproliferative syndrome (ALPS)
  • Autoinflammatory disorders e.g. familial Mediterranean fever (FMF)
  • Complement deficiencies e.g. hereditary angioedema (HAE)

Note: A published classification of conditions which cause PIDs has been developed by the International Union of Immunological Societies (IUIS), which is regularly modified. The current version divides PIDs into nine categories and refers to PIDs as Inborn Errors of Immunity. For the purpose of this document, the more readily recognised term of primary immunodeficiencies (PIDs) is used.

Research and advances in therapies have resulted in improved health and a longer life for people with PIDs. There are currently six main types of treatment options: 

  • Antibiotics
  • Immunoglobulin Replacement Therapy (IRT) - subcutaneous (SCIg) or intravenous (IVIg)
  • Immunomodulation – including biologics
  • Hereditary Angioedema (HAE) Treatments
  • Haematopoietic Stem Cell Transplantation (HSCT)
  • Gene Therapy

EARLY DIAGNOSIS AND SPECIALIST TREATMENT OF PID ENABLES PROFOUND BENEFITS

Because of their rarity, delays in diagnosis of PIDs are common, which is associated with further complications and reduced survival rates.

For infants and very young children with severe PIDs, diagnostic delay leads to severe complications due to infections and early death. Early diagnosis is vital to allow curative treatment such as urgent haematopoietic stem cell transplantation (HSCT), also known as bone marrow transplant (BMT).

For older children and adults where curative treatment is not possible, delay in diagnosis is associated with reduced life expectancy.

With targeted resources, patients with PID can be spared unnecessary interventions and instead utilise available medical treatments to maximise their opportunities to lead productive and healthy lives. 

Content updated November 2020


Working in collaboration with patient organisations and other stakeholders


© ASCIA Immunodeficiency Strategy 2020Contact Us | Disclaimer | Privacy | Sitemap